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Background
Regulatory T cells (Tregs) are thought to play a crucial role
in preventing and controlling hyperactive immune
responses in malignancies and inflammatory disease. The
role of Tregs in Kaposi's sarcoma (KS) has not been
explored and is of particular interest in that this disease
demonstrates characteristics of both inflammation and
malignancy. We examined the presence and frequency of
Tregs in KS tissue samples compared to normal skin. In
addition, we compared presence and frequency of Tregs
across three distinct histopathologic stages of KS. The his-
topathologic comparisons included the earlier patch and
plaque stages, and the most advanced, nodular stage of
KS.
Methods
Regulatory T cells are characterized by the expression of
FOXP3, CD4 and CD25. A total of 15 cutaneous KS sam-
ples were obtained from different patients. Of the total 15
KS samples, breakdown of histopathologic subtypes
included 6 samples from patches, 4 samples from
plaques, and 5 samples from nodules. Eight samples from
normal skin served as controls. Immunohistochemical
and immunofluorescent assays and image analysis were
performed on all samples.
Results
The frequency of FOXP3+ cells in all stages of KS was sig-
nificantly higher compared to normal skin with means ±
standard deviation of 43.4 ± 47.8 FOXP3+ cells/mm2 in
KS versus 4.56 ± 12.5 FOXP3+ cells/mm2 (p < 0.001). This
difference remained significant when comparing each
individual stage to normal skin (p <0.001 for nodular and
plaque stages versus normal skin, p = 0.002 for patch stage
versus normal skin). The number of FOXP3+ cells was
highest in the nodular stage 70.3 ± 47.8 FOXP3+ cells/
mm2 compared to both patch 29.3 ± 50.8 p = 0.001 and
plaque 27.8 ± 33.2 p < 0.001 stages. The frequency of
FOXP3+ cells in patch and plaque stages was not signifi-
cantly different.
Conclusion
Tregs are present in KS and are increasingly frequent in
advanced disease. This finding of increased Tregs in the
most advanced stage of KS is a phenomenon that has also
been demonstrated in other malignancies including
melanoma, ovarian cancer, and hepatocellular carci-
noma. Tregs might play a critical role in suppressing the
KS-specific immune response and contributing to the
unchecked proliferation that is characteristic of KS. In
addition, our finding that Tregs were markedly increased
in the most advanced stage of KS suggests that regulatory
T cells may also play a key role in KS progression. Ulti-
mately, targeted regulatory T cell immunotherapy may
lead to improved treatment response and prognosis.
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